SHIP蛋白质的生物学特性及其与白血病的关系

含SH2结构域的肌醇磷酸酶(SHIP)属于5’磷酸酯酶家族成员。SHIP能将磷脂酰肌醇-3,4,5-三磷酸(PI-3,4,5-P3,PIP3)水解为磷脂酰肌醇-3,4-二磷酸(PI-3,4-P2),是主要表达于造血细胞的磷脂酰肌醇3-激酶(PI3K)信号抑制分子,通过参与调节PI3K途径而影响细胞增殖、存活及信号转导等诸多细胞活动,与白血病的发生发展密切相关。     

PI3K/AKT通路在动物葡萄糖代谢中的研究进展

葡萄糖代谢稳态对维持动物健康水平至关重要。磷脂酰肌醇3-激酶(phosphoinositide 3-kinase,PI3K)是受体酪氨酸激酶(receptor tyrosine kinase, RTK)和G蛋白偶联受体(G protein-coupled receptor, GPCR)共同调控的下游效应因子。它能够磷酸化磷脂酰肌醇(phosphatidylinositol, PI)上肌醇环的D3羟基,生成第二信使磷脂酰肌醇-3,4,5-三磷酸(PI-3,4,5-P3, PIP3)。PIP3的生成可以促使蛋白激酶B(protein kinase B,AKT/PKB)在细胞膜处募集并诱导其变构激活,活化的AKT可以通过调节下游靶标的活性来调控机体的葡萄糖代谢过程和其他生物学功能。鉴于PI3K/AKT信号通路在动物机体葡萄糖代谢以及人类2型糖尿病(type2 diabetes mellitus, T2DM)等疾病中的重要调控作用,该文就PI3K/AKT信号通路及相关重要调控因子的生物学功能与分子机制进行综述。     

蛋白激酶B/Akt抑制剂

磷脂酰肌醇-3-激酶(phosphatidylinositol 3-kinase,PI3K)/蛋白激酶B(protein kinase B,PKB/Akt)信号通路在细胞生长与存活中起着关键作用,PI3K/Akt通路的过度激活在多种肿瘤中常见。Akt激酶本身以及Akt激酶上游调节分子,例如PTEN和PI3K,在超过50%的人类肿瘤中均有异常变化。因此Akt成为肿瘤预防和肿瘤靶向治疗的热点之一。许多小分子化合物通过不同机制抑制Akt活性,根据小分子抑制剂与激酶的结合部位和化学结构不同,主要分为ATP竞争性抑制剂、Akt变构抑制剂和磷脂酰肌醇类似物抑制剂。本文综述了PI3K/Akt通路与肿瘤的关系和Akt抑制剂的研究现状,为新型抗癌药物的设计研究提供参考。     

磷脂酰肌醇 -3 激酶不直接调控PC12 细胞的分泌

磷脂酰肌醇-3激酶(PI3K)是磷脂酰肌醇代谢过程中一种重要的酶,通过其代谢产物参与了对多种细胞生理活动的调节,如囊泡运输、细胞骨架重组、细胞存活、吞噬作用、细胞凋亡等.为研究其对细胞分泌功能的作用,使用磷脂酰肌醇-3激酶家族的特异性抑制剂渥曼青霉素(wortmannin)阻断磷脂酰肌醇-3激酶的活性,以EGFP-2xFYVE融合蛋白与磷脂酰肌醇-3-磷酸(PtdIns-3-P)的结合为指征,使用荧光显微成像技术检测渥曼青霉素对磷脂酰肌醇-3激酶的抑制作用,采用膜片钳膜电容测量方法及光解钙离子释放技术检测渥曼青霉素对PC12细胞分泌功能的影响.实验结果表明,wortmannin阻断了磷脂酰肌醇-3激酶的活性,抑制了磷脂酰肌醇-3-磷酸(PtdIns-3-P)的产生,并使FYVE与PtdIns-3-P解离,但渥曼青霉素处理之前和处理30 min后的PC12细胞分泌反应的幅度、动力学特性和分泌的钙依赖性均无显著差异,表明磷脂酰肌醇-3激酶对PC12细胞的分泌无显著的直接影响.     

PI3K 抑制剂抗肿瘤临床研究进展

磷脂酰肌醇-3-激酶 (PI3K) 是一种胞内磷脂酰肌醇激酶,在介导细胞生长、发育、分裂、分化和凋亡等过程中发挥重要作用,因此 PI3K 抑制剂的开发已成为当前抗癌新药研究的热点之一。目前已有多个 PI3K 抑制剂进入临床研究阶段或已上市,其单用或与其他药物联 用的疗效和安全性有待进一步临床验证。综述 PI3K 抑制剂作为抗肿瘤药物的临床研究进展,为其进一步研究与应用提供参考。     

PI3K-Akt信号传导通路对糖代谢的调控作用

磷脂酰肌醇3-激酶(PI3Ks)作为酪氨酸激酶和G蛋白偶联受体的主要下游分子,通过催化产生第二信使3,4,5-三磷酸磷脂酰肌醇(PIP3)并激活Akt、糖原合酶激酶-3(GSK-3)、Forkhead转录因子FoxO1、mTOR(mammalian target of rapamycin)等下游分子,将多种生长因子及细胞因子的信号传递到细胞内,从而对细胞增殖、分化、凋亡和葡萄糖转运等多种生物过程起重要的调节作用.PTEN(phosphatase and tensin homologue)是PI3K信号通路的重要负调节因子.本文将对PI3K-Akt信号通路在糖代谢中的作用予以简要综述.     

依加利塞（Eganelisib）的抗炎及其PI3Kγ选择性抑制机制研究

目的 磷脂酰肌醇3激酶γ (PI3Kγ)在免疫系统的调节中发挥重要作用,使其成为一个炎症治疗的潜在药物靶点。目前选择性PI3Kγ抑制剂用于治疗炎症的研究较为匮乏,PI3Kγ抑制剂的炎症治疗效果有待进一步揭示。因此,本课题选择目前已进入临床研究的PI3Kγ抑制剂依加利塞（Eganelisib）进行抗炎作用及PI3Kγ选择性机制研究。方法 首先通过脂多糖（LPS）诱导RAW264.7细胞,构建炎症细胞模型检测依加利塞的抗炎作用及机制。随后,通过联用分子共同特征药效团、受体-配体复合物药效团、分子动力学的计算模拟方法,在分子水平揭示依加利塞的PI3Kγ选择性作用抑制机制。结果 依加利塞可以通过抑制炎症细胞中的PI3K信号通路来抑制细胞炎症因子的释放;药效团模型揭示氢键及疏水是依加利塞产生PI3Kγ选择性抑制的关键药效团特征;分子动力学模拟发现了抑制剂与PI3Kγ蛋白选择性结合的关键氨基酸,包括Val882、Met804、Trp812、Ile963。结论 本研究初步验证了依加利塞的抗炎作用,并在分子水平揭示了抑制剂与PI3Kγ选择性结合机制,为抗炎PI3Kγ抑制剂的开发提供一定的指导作用。     

PPAR-γ作用及其相关信号转导途径

过氧化物酶增殖物激活受体(peroxisomeproliferater-activatedreceptor,PPAR)是一类配体激活的核转录因子超家族成员,包括PPAR-α、PPAR-β/δ和PPAR-γ三种表型,其中以PPAR-γ的研究最为深入。PPAR-γ通过JAK-STAT、激活蛋白-1(AP-1)、NF-κB、活化T细胞核因子信号通路(NFAT)来抑制炎症反应;通过抑制泡沫细胞(foamcell)的分化、炎症反应以及细胞增殖来抑制动脉粥样硬化的发生发展;通过磷脂酰肌醇-3激酶(PI3K)、瘦素、脂链素等信号通路来参与糖稳态的调节;通过细胞周期的调控来影响肿瘤生长;参与脂肪细胞分化并与肥胖密切相关。明确这些相关信号通路以及相关细胞因子的作用,可对相关疾病机制及防治进一步提供有力依据和干预途径。     

综述: Ⅲ型磷脂酰肌醇3-激酶复合物与自噬的研究进展

Ⅲ型磷脂酰肌醇3-激酶(class Ⅲ PI3K)是以磷脂酰肌醇(PtdIns)为底物催化产生PtdIns3 P的激酶,与多种不同的调节蛋白结合形成Ⅲ型PI3K(PI3KC3)复合物,在自噬及膜泡运输中起重要作用．PI3KC3复合物组成成员PI(3)KC3、p150、Beclin 1、ATG14L、UVRAG、Bif-1和Rubicon在进化上大多具有高度的同源性和保守性,并且与神经系统发育、胸腹腔内脏反位及肿瘤等多种疾病的发生和发展密切相关．     

缺失plcg1基因引起成纤维细胞PI—3K信号上调

磷脂酶C－γ1（phospholipase C－γ1,PLC－γ1）与磷脂酰肌醇3－激酶（phosphatidylinositol-3 kinase,PI-3K）是生长因子调控细胞生长与增殖的两个重要信号中介。为探讨PLC－γ1在表皮生长因子（EGF）介导的细胞分裂信号中的代偿机制,用磷脂酶C（phospholipase C,PLC）特异性抑制剂U73122及PI－3K牧场划必抑制剂wortmannin处理剔除PLC－δ1基因plcg1(PLC-γ1^-/-）及野生型（PLC－γ1^ / )小鼠胚胎成纤维细胞,发现未经处理情况下两种细胞的克隆形成能力、细胞活力及EGF引起的DNA合成能力相似,且均可被U73122与wortmannin抑制,但与PLC－γ1^ / 细胞相比,PLC－γ1^－／－更依赖于PI－3K,而对PLC的依赖性却减小。Western印迹也表明EGF刺激后PI－3K的p85α亚单位酷氨酸磷酸化程度比野生型显著增高,PI－3K信号通路的激活出现上调,且PLC－γ1^-/-中无基近亲PLC－γ2的代偿表达。因此PLC－γ1^-/-中PLC－γ1的功能可能被PI－3K通路代偿,而PLC－γ2或其他PLC同工酶并不代偿其功能。结果表明EGF介导的信号能路的冗余性及PLC－γ1信号通路的可代偿性。     

PI3K delta and PI3K gamma: partners in crime in inflammation in rheumatoid arthritis and beyond?

Dysregulated signal transduction in innate and adaptive immune cells is known to be associated with the development of various autoimmune and inflammatory diseases. Consequently, targeting intracellular signalling of the pro-inflammatory cytokine network heralds hope for the next generation of anti-inflammatory drugs. Phosphoinositide 3-kinases (PI3Ks) generate lipid-based second messengers that control an array of intracellular signalling pathways that are known to have important roles in leukocytes. In light of the recent progress in the development of selective PI3K inhibitors, and the beneficial effects of these inhibitors in models of acute and chronic inflammatory disorders, we discuss the therapeutic potential of blocking PI3K isoforms for the treatment of rheumatoid arthritis and other immune-mediated diseases.     

PI3K inhibition in inflammation: Toward tailored therapies for specific diseases

In the past decade, the availability of genetically modified animals has enabled the discovery of interesting roles for phosphatidylinositol 3‐kinase‐γ (PI3Kγ) and ‐δ (PI3Kδ) in different cell types orchestrating innate and adaptive immune responses. Therefore, these PI3K isoforms appear to be attractive drug targets for the treatment of diseases caused by unrestrained immune reactions. Currently, pharmacological targeting of PI3Kγ and/or PI3Kδ represents one of the most promising challenges for companies interested in the development of novel safe treatments for inflammatory diseases. In this review we provide a general outline of PI3Kγ‐ and PI3Kδ‐specific functions in distinct subsets of inflammatory cells. We also discuss the therapeutic impact of novel compounds targeting PI3Kγ, PI3Kδ or both, in mouse models of autoimmune disorders (systemic lupus erythematosus (SLE) and rheumatoid arthritis), respiratory diseases (allergic asthma and chronic obstructive pulmonary disease) and cardiovascular dysfunctions (atherosclerosis and myocardial infarction).     

Phylogenomics of phosphoinositide lipid kinases: perspectives on the evolution of second messenger signaling and drug discovery

Background  

Phosphoinositide lipid kinases (PIKs) generate specific phosphorylated variants of phosatidylinositols (PtdIns) that are critical for second messenger signaling and cellular membrane remodeling. Mammals have 19 PIK isoforms spread across three major families: the PtIns 3-kinases (PI3Ks), PtdIns 4-kinases (PI4Ks), and PtdIns-P (PIP) kinases (PIPKs). Other eukaryotes have fewer yet varying PIK complements. PIKs are also an important, emerging class of drug targets for many therapeutic areas including cancer, inflammatory and metabolic diseases and host-pathogen interactions. Here, we report the genomic occurrences and evolutionary relationships or phylogenomics of all three PIK families across major eukaryotic groups and suggest potential ramifications for drug discovery.     

The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

Phosphatidylinositol 3-kinases (PI3Ks) evolved from a single enzyme that regulates vesicle trafficking in unicellular eukaryotes into a family of enzymes that regulate cellular metabolism and growth in multicellular organisms. In this review, we examine how the PI3K pathway has evolved to control these fundamental processes, and how this pathway is in turn regulated by intricate feedback and crosstalk mechanisms. In light of the recent advances in our understanding of the function of PI3Ks in the pathogenesis of diabetes and cancer, we discuss the exciting therapeutic opportunities for targeting this pathway to treat these diseases.     

The susceptibility of trypanosomatid pathogens to PI3/mTOR kinase inhibitors affords a new opportunity for drug repurposing

Background

Target repurposing utilizes knowledge of “druggable” targets obtained in one organism and exploits this information to pursue new potential drug targets in other organisms. Here we describe such studies to evaluate whether inhibitors targeting the kinase domain of the mammalian Target of Rapamycin (mTOR) and human phosphoinositide-3-kinases (PI3Ks) show promise against the kinetoplastid parasites Trypanosoma brucei, T. cruzi, Leishmania major, and L. donovani. The genomes of trypanosomatids encode at least 12 proteins belonging to the PI3K protein superfamily, some of which are unique to parasites. Moreover, the shared PI3Ks differ greatly in sequence from those of the human host, thereby providing opportunities for selective inhibition.

Methodology/Principal Findings

We focused on 8 inhibitors targeting mTOR and/or PI3Ks selected from various stages of pre-clinical and clinical development, and tested them against in vitro parasite cultures and in vivo models of infection. Several inhibitors showed micromolar or better efficacy against these organisms in culture. One compound, NVP-BEZ235, displayed sub-nanomolar potency, efficacy against cultured parasites, and an ability to clear parasitemia in an animal model of T. brucei rhodesiense infection.

Conclusions/Significance

These studies strongly suggest that mammalian PI3/TOR kinase inhibitors are a productive starting point for anti-trypanosomal drug discovery. Our data suggest that NVP-BEZ235, an advanced clinical candidate against solid tumors, merits further investigation as an agent for treating African sleeping sickness.     

Class II phosphoinositide 3-kinase C2alpha: what we learned so far

More than fifteen years after the first identification of a class II isoform of phosphoinositide 3-kinase (PI3K) in Drosophila melanoǵaster this subfamily remains the most enigmatic among all PI3Ks. What are the functions of these enzymes? What are their mechanisms of activation? Which downstream effectors are specifically regulated by these isoforms? Are class I and class II PI3Ks redundant or do they control different intracellular processes? And, more important, do class II PI3Ks have a role in human diseases? The recent increased interest on class II PI3Ks has started providing some answers to these questions but still a lot needs to be done to completely uncover the contribution of these enzymes to physiological processes and possibly to pathological conditions. Here we will summarise the recent findings on the alpha isoform of mammalian class II PI3Ks (PI3K-C2α ) and we will discuss the potential involvement of this enzyme in human diseases.     

Phosphoinositide 3-kinase delta (PI3Kδ) in leukocyte signaling and function

PI3Kδ is a lipid kinase of the PI3K class IA family involved in early signaling events of leukocytes responding to a wide variety of stimuli. The leukocyte specificity of PI3Kδ is defined by its expression, whereas its signaling function is via the production of phosphoinositide 3,4,5-triphosphates at the proximity of activated receptors for recruiting other signaling molecules. The importance of PI3Kδ in B cell development and function is most apparent, and its role in other leukocyte cell types can be easily demonstrated as well. PI3Kδ participates in the development, activation and migration of T cells and NK cells. The role of PI3Kδ in myeloid cell activities, such as inflammation driven cell infiltration, neutrophil oxidative burst, immune complex mediated macrophage activation, as well as mast cell maturation and degranulation, has been well illustrated in various studies. As a result of the broad effects of PI3Kδ in leukocyte functions, the disruption of PI3Kδ expression or activity leads to decreased inflammatory and immune responses in vivo. The protective role of PI3Kδ inactivation in animal models of arthritis, asthma or obstructive respiratory diseases has been demonstrated. These findings suggest the potential efficacy achievable with PI3Kδ inhibitors in the treatment of autoimmune and respiratory diseases.     

Enforced expression of miR-92b blunts E. coli lipopolysaccharide-mediated inflammatory injury by activating the PI3K/AKT/β-catenin pathway via targeting PTEN

Endometritis is a reproductive disorder characterized by an inflammatory response in the endometrium, which causes significant economic losses to the dairy farming industry. MicroRNAs (miRNAs) are implicated in the inflammatory response and immune regulation following infection by pathogenic bacteria. Recent miRNA microarray analysis showed an altered expression of miR-92b in cows with endometritis. In the present study, we set out to investigate the regulatory mechanism of miR-92b in endometritis. Here, qPCR results first validated that miR-92b was down-regulated during endometritis. And then, bovine endometrial epithelial cells (BEND cells) stimulated by high concentration of lipopolysaccharide (LPS) were employed as an in vitro inflammatory injury model. Our data showed that overexpression of miR-92b significantly suppressed the activation of Toll-like receptor 4 (TLR4) and nuclear factor-κB (NF‐κB) in LPS-stimulated BEND cells, thereby reducing pro-inflammatory cytokines release and inhibiting cell apoptosis. Looking into the molecular mechanisms of regulation of inflammatory injury by miR-92b, we observed that overexpression of miR-92b restrained TLR4/NF‐κB by activating the phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT)/β-catenin pathway. Furthermore, the luciferase reporter assay suggested that miR-92b targeted inhibition of phosphatase and tensin homolog (PTEN), an inhibitor of the PI3K/AKT/β-catenin pathway. Importantly, in vivo experiments confirmed that up-regulation of miR-92b attenuated the pathological injury in an experimental murine model of LPS-induced endometritis. Collectively, these findings show that enforced expression of miR-92b alleviates LPS-induced inflammatory injury by activating the PI3K/AKT/β-catenin pathway via targeting PTEN, suggesting a potential application for miR-92b-based therapy to treat endometritis or other inflammatory diseases.     

α7烟碱型乙酰胆碱受体在胆碱能抗炎通路中的作用机制及应用现状

胆碱能抗炎通路是一条神经-免疫调节通路,以中枢神经系统的迷走神经为起点,以神经递质乙酰胆碱为基础,以免疫细胞膜表面的α7烟碱型乙酰胆碱受体(α7 nicotinic acetylcholine receptor, α7 nAChR)为关键作用位点。其中,电信号与化学信号相互转化,激活JAK-STAT3、PI3K-Akt等信号通路,抑制NF-κB的核转位,进而抑制促炎因子的释放,促进抑炎因子的释放,调节和控制机体的炎症,具体的作用机制正在研究中。研究表明,可以通过使用药物激活α7 nAChR和电刺激迷走神经这2种方法,激活胆碱能抗炎通路。其中,激活α7 nAChR具有操作简便、创伤小和效果显著等优势。常用药物有选择性激动剂,例如PNU282987和GTS-21等,非选择性激动剂例如烟碱。多项研究显示,该方法在脓毒症、缺血再灌注、胃肠炎、骨关节炎和自身免疫病等外周器官炎性疾病治疗中都具有一定的效果。α7 nAChR作为胆碱能抗炎通路的关键作用位点,成为许多炎性疾病的潜在治疗靶点,本文对胆碱能抗炎通路中的α7 nAChR所涉及的抗炎机制、通路激活方式,以及其近年来在炎性疾病中的应用进行了综述,为未来研究其具体作用机制和新的治疗靶点提供参考。     

Design and synthesis of phenethyl benzo[1,4]oxazine-3-ones as potent inhibitors of PI3Kinasegamma

The Type 1 PI3Kinases comprise a family of enzymes, which primarily phosphorylate PIP2 to give the second messenger PIP3, a key player in many intracellular signaling processes [Science, 2002, 296, 1655; Trends Pharmacol. Sci.2003, 24, 366]. Of the four type 1 PI3Ks, the gamma-isoform, which is expressed almost exclusively in leukocytes [Curr. Biol., 1997, 7, R470], is of particular interest with respect to its role in inflammatory diseases such as rheumatoid arthritis (RA) and chronic obstructive pulmonary disease (COPD) [Mol. Med. Today, 2000, 6, 347]. Investigation of a series of 4,6-disubstituted-4H-benzo[1,4]oxazin-3-ones has led to the identification of single-digit nanomolar inhibitors of PI3Kgamma, several of which had good cell based activity and were shown to be active in vivo in an aspectic peritonitis model of inflammatory cell migration.